Form 4: Krystal Biotech Director Julian S. Gangolli Awarded Stock Options

Director Julian S. Gangolli of Krystal Biotech, Inc. reports the acquisition of stock options.

Summary

• Julian S. Gangolli, a director of Krystal Biotech, Inc., filed a Form 4 on July 1, 2024, reporting a transaction.
• On June 30, 2024, Gangolli was awarded stock options to purchase 5,000 shares of Krystal Biotech common stock at an exercise price of $183.64 per share.
• The options vest in equal monthly tranches over a one-year period and expire on June 30, 2034.
• Following the transaction, Gangolli directly owns options for 5,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance.

Positives

• The awarding of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company's success.

Future Outlook

NA

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the options are exercised at a price higher than the grant price, reflecting company growth.

Key Dates